Angle PLC Announces 100th Publication Supporting Parsortix System Use
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the 100th peer-reviewed journal article using its Parsortix® system for circulating tumour cell (CTC) analysis. The latest publication, from researchers at Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano, reports on using the Parsortix system to isolate CTCs from triple negative breast cancer patients for whole genomic sequencing (WGS).
The study used machine learning to identify cancer genes associated with DNA proliferation and repair. The authors conclude that this cost-effective sequencing assay has potential to guide clinical patient management. The 100 publications span a decade of research across 24 cancer types, involving 42 independent institutions in 15 countries.
ANGLE's Chief Scientific Officer, Karen Miller, highlighted that CTC analysis has evolved from simple enumeration to detailed biomarker analysis using advanced techniques. She emphasized the potential of multi-analyte assessment in liquid biopsy as a less invasive and more cost-effective alternative to tissue biopsy.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) annuncia il 100° articolo scientifico sottoposto a revisione paritaria che utilizza il suo sistema Parsortix® per l'analisi delle cellule tumorali circolanti (CTC). L'ultima pubblicazione, realizzata da ricercatori della Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano, riporta l'uso del sistema Parsortix per isolare le CTC dai pazienti con cancro al seno triplo negativo per una sequenza genomica completa (WGS).
Lo studio ha utilizzato l'apprendimento automatico per identificare i geni del cancro associati alla proliferazione e riparazione del DNA. Gli autori concludono che questo test di sequenziamento conveniente ha il potenziale di guidare la gestione clinica dei pazienti. Le 100 pubblicazioni coprono un decennio di ricerca su 24 tipi di cancro, coinvolgendo 42 istituzioni indipendenti in 15 paesi.
Il Chief Scientific Officer di ANGLE, Karen Miller, ha sottolineato che l'analisi delle CTC è evoluta da una semplice enumerazione a un'analisi dettagliata dei biomarcatori utilizzando tecniche avanzate. Ha enfatizzato il potenziale della valutazione multi-analita in biopsie liquide come alternativa meno invasiva e più conveniente alla biopsia tissutale.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) anuncia el 100º artículo revisado por pares que utiliza su sistema Parsortix® para el análisis de células tumorales circulantes (CTC). La última publicación, realizada por investigadores de la Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano, informa sobre el uso del sistema Parsortix para aislar CTC de pacientes con cáncer de mama triple negativo para secuenciación genómica completa (WGS).
El estudio utilizó aprendizaje automático para identificar genes del cáncer asociados con la proliferación y reparación del ADN. Los autores concluyen que esta prueba de secuenciación rentable tiene el potencial de guiar la gestión clínica del paciente. Las 100 publicaciones abarcan una década de investigación en 24 tipos de cáncer, involucrando 42 instituciones independientes en 15 países.
La Directora Científica de ANGLE, Karen Miller, destacó que el análisis de CTC ha evolucionado de una simple enumeración a un análisis detallado de biomarcadores utilizando técnicas avanzadas. Enfatizó el potencial de la evaluación multianalítica en biopsias líquidas como una alternativa menos invasiva y más rentable a la biopsia de tejido.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY)는 순환 종양 세포(CTC) 분석을 위해 자사의 Parsortix® 시스템을 사용한 100번째 동료 검토 저널 기사를 발표했습니다. 최근 밀라노 국립 종양 연구소의 Fondazione IRCCS 연구자들이 발표한 연구에서는 전체 유전체 시퀀싱(WGS)을 위해 삼중 음성 유방암 환자에서 CTC를 분리하는 Parsortix 시스템의 사용을 보고합니다.
이 연구는 DNA 증식 및 수리와 관련된 암 유전자를 식별하기 위해 기계 학습을 사용했습니다. 저자들은 이 비용 효율적인 시퀀싱 검사가 임상 환자 관리를 안내할 가능성이 있다고 결론지었습니다. 이번에 발표된 100개의 논문은 24종의 암에 걸쳐 10년간의 연구 결과를 담고 있으며, 15개국의 42개 독립 기관이 참여했습니다.
ANGLE의 수석 과학 책임자(Karen Miller)는 CTC 분석이 단순한 셈 인간 작업에서 고급 기법을 활용한 상세한 바이오마커 분석으로 발전해왔음을 강조했습니다. 그녀는 액체 생검에서 다중 분석 평가가 조직 생검에 대한 덜 침습적이고 비용 효율적인 대안이 될 수 있는 가능성을 강조했습니다.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) annonce le 100ème article de revue par les pairs utilisant son système Parsortix® pour l'analyse des cellules tumorales circulantes (CTC). La dernière publication, émanant de chercheurs de la Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano, concerne l'utilisation du système Parsortix pour isoler des CTC chez des patientes atteintes de cancer du sein triple négatif pour séquençage génomique complet (WGS).
L'étude a utilisé l'apprentissage automatique pour identifier les gènes cancéreux associés à la prolifération et à la réparation de l'ADN. Les auteurs concluent que ce test de séquençage rentable a un potentiel pour guider la gestion clinique des patients. Les 100 publications s'étalent sur une décennie de recherche dans 24 types de cancer, impliquant 42 institutions indépendantes dans 15 pays.
La Directrice scientifique d'ANGLE, Karen Miller, a souligné que l'analyse des CTC a évolué d'une simple énumération vers une analyse détaillée des biomarqueurs à l'aide de techniques avancées. Elle a mis en avant le potentiel de l'évaluation multi-analyte dans la biopsie liquide comme une alternative moins invasive et plus rentable à la biopsie tissulaire.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) gibt die 100. von Peer-Review geprüfte wissenschaftliche Publikation bekannt, die ihr Parsortix®-System zur Analyse von zirkulierenden Tumorzellen (CTC) verwendet. Die neueste Veröffentlichung von Forschern der Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano berichtet über die Anwendung des Parsortix-Systems zur Isolierung von CTCs von Patientinnen mit triple-negativem Brustkrebs für die komplette genomische Sequenzierung (WGS).
Die Studie nutzte maschinelles Lernen, um Krebs-assoziierte Gene zu identifizieren, die mit der DNA-Proliferation und -Reparatur in Verbindung stehen. Die Autoren schließen, dass dieser kostengünstige Sequenzierungstest das Potenzial hat, das klinische Patientenmanagement zu leiten. Die 100 Publikationen erstrecken sich über ein Jahrzehnt der Forschung zu 24 Krebsarten und umfassen 42 unabhängige Institutionen in 15 Ländern.
Der Chief Scientific Officer von ANGLE, Karen Miller, hob hervor, dass die CTC-Analyse sich von einer einfachen Zählung zu einer detaillierten Biomarker-Analyse mit fortschrittlichen Techniken entwickelt hat. Sie betonte das Potenzial der multi-analyten Bewertung in der Flüssigbiopsie als weniger invasive und kostengünstigere Alternative zur Gewebeentnahme.
- Reached milestone of 100 peer-reviewed publications using Parsortix system
- Research spans 24 cancer types responsible for 90% of solid cancer cases
- Involvement of 42 independent research institutes, hospitals, and universities across 15 countries
- Evolution of CTC analysis from simple enumeration to detailed biomarker analysis
- Potential for Parsortix system to guide clinical patient management in cancer treatment
- None.
GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair
ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of the 100th peer-reviewed journal article using the Parsortix® system for the isolation, harvest and analysis of CTCs.
The journal article is published by researchers from a leading international referral centre for the treatment and study of cancer, the Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano (Italy). It reports on the isolation of CTCs from triple negative breast cancer patients for analysis using single cell isolation and whole genomic sequencing (WGS). WGS is the most comprehensive genetic test available, sequencing an individual's entire genome to reveal unique mutations that may be present in cancer cells. Although not yet routinely used in clinical practice, WGS can allow the identification of genetic drivers of cancer and potential new targeted treatments. In this study the Parsortix system harvested intact cancer cells from patient blood samples for WGS. Sequencing data was analysed using a machine learning algorithm to identify cancer genes associated with DNA proliferation and repair. The authors conclude that this cost-effective sequencing assay has the potential to guide clinical patient management.
The 100 publications using the Parsortix system span a decade of research across 24 cancer types responsible for
Chief Scientific Officer, Karen Miller, commented:
"This publication marks a decade of independent research where the Parsortix system has been used to provide insights into tumour biology, metastatic progression and treatment response.
Whilst ctDNA profiling is more established in the clinic, in recent years there has been an increase in the number of publications analysing both CTCs and ctDNA. These studies have found that CTCs can provide additional and complementary information to ctDNA or tissue alone and therefore a more comprehensive view of the tumour and its interaction with the microenvironment. We firmly believe that multi-analyte assessment holds the potential to unlock the full clinical capabilities of liquid biopsy as a less invasive and more cost-effective alternative to tissue biopsy."
The research has been published as a peer-reviewed publication in the journal Scientific Reports is available online at https://angleplc.com/resources/publications/.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Products include the Parsortix system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What milestone has ANGLE plc (ANPCY) announced regarding its Parsortix system?
What does the latest study using ANGLE's Parsortix system (ANPCY) focus on?
How many cancer types and countries are represented in the research using ANGLE's Parsortix system (ANPCY)?
What potential benefit does ANGLE's (ANPCY) Chief Scientific Officer highlight about their Parsortix system?
